Summary:
The Kuwahara et al. 1988 Kuwahara et al. , 1996 and applied it to sleep experiments using various drugs (Mizuki et al. 1988; Tanaka et al. 1988; Suetsugi et al. 1992 Suetsugi et al. , 1995 . In this report, investigation of the effects of a benzodiazepine anxiolytic drug, ethyl loflazepate (CM6912), on EEGs, as assessed by the analytical procedure, is described. second night according to Agnew et al. (1966) ; according to Touyz et al. (1978) , there was no significant difference between the baseline night and the drug night (when a placebo was administered) or between the baseline night and the recovery night in the experimental schedule including two adaptation nights, 2 baseline nights, 3 drug nights (when a placebo was administered) and 2 recovery nights. From these findings, the first night effect may have been present on the second baseline night, but it was estimated to have already been absent or to have been minima on the third baseline night. The reasons for the previously described tendencies of some parameters in stage 2, stage 3 and REM sleep on the third baseline night remain obscure. However, in consideration of the 5% significance level and the remarkable influence of drug administration, described below, no major problems were encountered in the use of the night as a control in this short-term experimental schedule. Thus, the mean value of the night was used as the wave-form parameter for the baseline night. ( Fig. 2) . Thus, the evaluation of timecourse changes allows visual observation of the relationship between sleep stage and EEG changes.
Changes in EEG patterns due to administration of CM6912 Tables 2 through 6 show changes in wave-form parameters in each sleep stage on the baseline night (average for the second and third baseline nights), first drug night, second drug night, and the recovery night. Individual stages showed the following characteristics. 
